Natco Pharma update on its key technical product - Chlorantraniliprole

CTPR is an active ingredient used in products commercialized by FMC under their brands Coragen & Ferterra. The sales generated from CTPR containing products in India, inclusive of third-party marketing companies, as per declaration given by FMC is estimated to be Rs 1540 crore in 2016. NATCO has filed a suit for declaration of freedom to use of CTPR, at the City Civil Court, Hyderabad, in the month of September 2019. FMC has counter-sued before the Delhi High Court, in November 2019, claiming patent infringement.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
More From This Section
Don't miss the most important news and views of the day. Get them on our Telegram channel
First Published: Nov 11 2019 | 3:44 PM IST
